EA201992628A1 - BCL6 INHIBITORS OBTAINED FROM BENZIMIDAZOLONE - Google Patents

BCL6 INHIBITORS OBTAINED FROM BENZIMIDAZOLONE

Info

Publication number
EA201992628A1
EA201992628A1 EA201992628A EA201992628A EA201992628A1 EA 201992628 A1 EA201992628 A1 EA 201992628A1 EA 201992628 A EA201992628 A EA 201992628A EA 201992628 A EA201992628 A EA 201992628A EA 201992628 A1 EA201992628 A1 EA 201992628A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bcl6
benzimidazolone
inhibitors obtained
compounds
activity
Prior art date
Application number
EA201992628A
Other languages
Russian (ru)
Inventor
Бенджамин Ричард Беллени
Майкл Кит Картер
Квай Мин Джэк Чын
Оуэн Александер Дэвис
Свен Хёлдер
Мэттью Гарт Ллойд
Ана Варела Родригез
Ханна Вудворд
Паоло Инноченти
Original Assignee
Кэнсер Рисерч Текнолоджи Лимитед
Де Инститьют Оф Кэнсер Рисерч: Роял Кэнсер Хоспитал
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кэнсер Рисерч Текнолоджи Лимитед, Де Инститьют Оф Кэнсер Рисерч: Роял Кэнсер Хоспитал filed Critical Кэнсер Рисерч Текнолоджи Лимитед
Priority claimed from PCT/GB2018/051447 external-priority patent/WO2018215801A1/en
Publication of EA201992628A1 publication Critical patent/EA201992628A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к соединениям формулы I, которые выполняют функцию ингибиторов активности BCL6 (белка В-клеточной лимфомы 6)где каждый из X, X, R, Rи Rопределен в данном документе. Настоящее изобретение также относится к способам получения данных соединений, к фармацевтическим композициям, содержащим их, и к их применению в лечении пролиферативных нарушений, таких как рак, а также других заболеваний или состояний, в которые вовлечена активность BCL6.The present invention relates to compounds of formula I, which act as inhibitors of the activity of BCL6 (protein B-cell lymphoma 6) where each of X, X, R, R and R is defined herein. The present invention also relates to methods for producing these compounds, to pharmaceutical compositions containing them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is involved.

EA201992628A 2018-04-13 2018-05-25 BCL6 INHIBITORS OBTAINED FROM BENZIMIDAZOLONE EA201992628A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1806130.9A GB201806130D0 (en) 2018-04-13 2018-04-13 Inhibitor compounds
PCT/GB2018/051447 WO2018215801A1 (en) 2017-05-26 2018-05-25 Benzimidazolone derived inhibitors of bcl6

Publications (1)

Publication Number Publication Date
EA201992628A1 true EA201992628A1 (en) 2020-04-29

Family

ID=62203320

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992628A EA201992628A1 (en) 2018-04-13 2018-05-25 BCL6 INHIBITORS OBTAINED FROM BENZIMIDAZOLONE

Country Status (2)

Country Link
EA (1) EA201992628A1 (en)
GB (1) GB201806130D0 (en)

Also Published As

Publication number Publication date
GB201806130D0 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
JOP20210154B1 (en) Kif18a inhibitors
MX2021007104A (en) Kif18a inhibitors.
MX2022001302A (en) Pyridine derivatives as kif18a inhibitors.
MX2021007157A (en) Heteroaryl amides useful as kif18a inhibitors.
MX2021007158A (en) Heteroaryl amides useful as kif18a inhibitors.
EA202190006A1 (en) PURINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
MX2023005636A (en) Benzimidazolone derived inhibitors of bcl6.
MX2022001181A (en) Kif18a inhibitors.
EA202091709A1 (en) DNA PC INHIBITORS
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
MX2023004920A (en) Bcl6 inhibitors.
EA202092086A1 (en) ARGINASE INHIBITORS
EA201991894A1 (en) PIPERIDINE-SUBSTITUTED Mnk INHIBITORS AND RELATED WAYS
EA202091708A1 (en) DNA PC INHIBITORS
EA201990678A1 (en) Heteroarylcarboxamide Compounds as Ripk2 Inhibitors
EA201291055A1 (en) PROTEINTIROZINKINASE ACTIVITY INHIBITORS AND THEIR APPLICATION FOR THE TREATMENT OF EYE DISEASES
EA202190588A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
EA202191478A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
EA202090414A1 (en) COMPOUNDS AND THEIR APPLICATION
EA202191476A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
EA202092326A1 (en) BUMETHANIDE DERIVATIVES FOR THE TREATMENT OF HYPERHYDROSIS
MX2019013562A (en) Fused heteroaromatic-aniline compounds for treatment of dermal disorders.
EA202191477A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
EA202092446A1 (en) THIAZOL- OR THIADIAZOL-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS Vps34 INHIBITORS
EA201992628A1 (en) BCL6 INHIBITORS OBTAINED FROM BENZIMIDAZOLONE